Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : International Isotopes (INIS) -- Ignore unavailable to you. Want to Upgrade?

To: Matt Black who wrote (29)	3/24/1998 2:51:00 PM
From: Barry Day	Respond to of 81

Matt: Great post! It's always good to read an intelligent post. It does appear we are having a normal pullback with an exceptional stock. In my eyes it's an extremely good looking chart. It does appear that there is a fair amount of short selling taking place. I do believe that the last rally was some short covering.????????

To: Matt Black who wrote (29)	3/24/1998 3:15:00 PM
From: BDR	Read Replies (1) \| Respond to of 81

<< It takes about 20 to 30 seeds for one operation in the prostate treatment which is just one application.>> A small correction: I don't know the average number of seeds implanted and I don't have extensive implant experience but I have never implanted less than 65 seeds and have implanted as many as 120. But ask a radiation therapist, I am sure they have a better handle on the numbers. 20 to 30 per case is too low.

To: Matt Black who wrote (29)	3/24/1998 6:09:00 PM
From: mantle7	Respond to of 81

Sorry Matt, but I think there are some pretty big holes in your logic, big enough for the more established competitors to drive through, namely: 1. In radiation manufacturing cross contamination of the equipment and physical plant is a major issue. You can not switch from vanilla to chocolate to strawberry at will, as you screw up the next guy's isotope. New isotopes mean new equipment and a new wing of a building. I think this will be a major issue to your expectation that INIS can sit back and watch all the orders come in. 2. Having your own FDA approved product is the major valuing creating opportunity for a medical device company. It is a significant barrier to entry. You are dreaming if you think 100+ companies can instantaneously give them business. The 510-k approval generally takes at least a year to a knock-off product, where one copies someone else's product. 3. Sealed sources for prostate is a commodity business. Low cost will ultimately win, and low cost must include the whole chain of manufacturing and distribution. If INIS only controls manufacturing, I believe they are at a long-term disadvantage. 4. I will believe the production this summer when it happens. ISO9002 for a manufacturing facility takes a good year. The isotopes must be approved by the NRC, etc. My point is that if your not already in the business it will be very tough to catch up later. Sure there is a tremendous backlog now, but the competitors are not sitting on their duffs. 5. I do own Mentor stock and I believe they are a significant better distribution partner than Imagyn, so is JNJ and Amersham for that matter. The question was, who is better INIS or NASI. NASI is ready to go right now. You are correct INIS got a great deal on the equipment and I believe they have a bright future. I believe it is a few years off however.